Hardy Alexander 4

What Happened
Hardy Alexander, CEO of BioMarin Pharmaceutical (BMRN), received equity awards on March 16, 2026: 62,440 restricted stock units (RSUs) and 89,200 derivative shares (option-related grant). Prior to those awards, 2,941 shares were surrendered on March 13, 2026 to cover an exercise price or tax liability at $58.51 per share, totaling $172,078 (disposition under withholding). The awards were reported as acquisitions at $0.00 (typical for grants/awards on Form 4).

Key Details

• Transactions:
  • 2026-03-13: 2,941 shares disposed (tax/withholding) at $58.51 → $172,078.
  • 2026-03-16: 62,440 RSUs granted (Acquired; price N/A).
  • 2026-03-16: 89,200 derivative award granted (Acquired; reported $0.00).
• Shares owned after the transactions: Not specified in the provided excerpt of the filing.
• Footnotes:
  • F1: Restricted stock units granted March 16, 2026 (price not applicable).
  • F2: Option grant vesting schedule — 12/48th vests on March 16, 2027, then 1/48th on the 16th of each subsequent month.
• Filing timeliness: Form filed March 17, 2026 for transactions on March 13 and March 16; no late-filing flag indicated in the provided data.

Context

• The March 13 disposition was a withholding to cover tax or exercise obligations (code F), not an open-market sale — common when executives receive equity.
• The 89,200 "derivative" grant appears to be an option-type award subject to the vesting schedule in F2; these do not represent immediately tradeable shares until vested/exercised.
• RSU grants and option awards are ongoing compensation and vest over time; they indicate ownership opportunity but are not direct cash purchases.